Enasidenib Mesylate vs Trastuzumab

Enasidenib Mesylate vs Trastuzumab: Overview

This comparison examines the pharmacological differences between Enasidenib Mesylate and Trastuzumab.

Mechanism of Action

Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

Pharmacokinetics

Half-life: Trastuzumab — 28 days.

Chemical Properties

Type: Enasidenib Mesylate — Small molecule; Trastuzumab — Antibody.